Effexor XR (venlafaxin HCI)


Approval Status
Approved October 1997

Treatment for

Possible similar drugs

Diabetes / Endocrinology , Psychiatry / Psychiatric

Wyeth-Ayerst Laboratories received marketing clearance from the U.S. Food and Drug Administration for Effexor (R) XR (venlafaxine HCI) Extended-Release Capsules. This is a once-a-day treatment that relieves the symptoms of depression. Clinical trial results also showed that patients receiving Effexor XR for the treatment of depression experienced a reduction in anxiety symptoms.

The most common side effects of Effexor included abnormal dreams, abnormal ejaculation, anorexia, dizziness, dry mouth, nausea, nervousness, somnolence, sweating and tremor.

Effexor XR (venlafaxin HCI) Drug Information

The Effexor XR (venlafaxin HCI) drug information shown above is licensed from Thomson CenterWatch. The information provided here is for general educational purposes only and does not constitute medical or pharmaceutical advice which should be sought from qualified medical and pharmaceutical advisers.

Scroll to top